Prolonging the survival of patients with gastric cancer

Florian Lordick. Foto: Stefan Straube / UKL International study shows that treating gastric cancer with new antibody has positive effects Gastric cancer is the fifth most commonly diagnosed malignancy worldwide. It ranks a sad third in cancer-related causes of death. The reason for this is late diagnosis coupled with rapid spread of tumour cells in the body. In an international clinical study co-chaired by investigators from Leipzig University's Faculty of Medicine, researchers investigated a substance that is expected to prolong the survival of patients and also established a new clinically relevant biomarker. The results have been published in the renowned journal -The Lancet-. -The results of the study are important for cancer research.